This award is closed
The Recurrent Pregnancy Loss Association (RPLA) in partnership with The American Society of Reproductive Medicine (ASRM) invites submission of application for its Research Award. This annual award will total up to $40,000 for a two-year study period. The purpose of this grant is to support innovative research projects that provide insights into causes, diagnosis, management, or parthenogenesis of recurrent pregnancy loss.
The applicant must demonstrate a strong career goal within the field of Reproductive Medicine and must be dedicated to the advancement of reproductive health and recurrent pregnancy loss research. Research proposals can involve physiological, psychological, biochemical, pharmacological, genetic, environmental, or pathological investigations.
An award, not to exceed $40,000, will be made May 2022.
Applicants must be actively working in areas related to reproductive medicine in the United States. The principal investigator (PI) must: (1) Have earned an M.D. and/or Ph.D. and/or D.O. and/or D.V.M. degree or their equivalents; (2) Be an independent investigator serving as a full-time clinician (academic or private practice) or holding a research staff position; (3) Fellows and postdoctoral trainees may apply but must complete the project prior to their program completion.
- Title page
- Title of the project (not to exceed 200 characters including spaces)
- Applicant’s name and credentials
- Applicant’s, department affiliation sponsoring institution, and contact information.
- Chairman/Division Chief letter (no more than two pages) acknowledging the applicant’s project and grant proposal, endorsing the applicant’s research, and confirming the institution’s commitment to provide time and support to the applicant.
- IF YOU ARE A FELLOW: Applicant letter stating career goals and plans for achieving these goals., including a lay statement of 2-3 sentences describing the relevance of the proposed research.
- Abstract (One page maximum)
- Scientific Abstract (500 words) describing the research proposal including the potential immediate impact of the anticipated results on the practice of reproductive medicine.
- Lay-person Abstract (200 words) describing the project in general terms
- Specific Aims of the research proposal presented in NIH format– (One page maximum)
- A research proposal should include the following sections (no more than three pages)
- Background and Significance
- Innovation and Potential Impact
- Research Plan (methodology and statistical analysis plan must be clearly described)
- Timeline for project start up, implementation, and completion
- References/citations are required but do not count against the total number of pages for the application. You may also include them as an appendix.
- NIH-style Biosketch
- Each Biosketch should include a specific description of the role of each investigator in the proposed project and should not exceed FIVE pages (including the current funding).
- A detailed yearly and cumulative budget and budget justification for the project.
- Conference travel and/or registration expenses to presented results related to this award.
- Funds may NOT be used towards degree seeking courses, cost of routine clinical care, or investigator salary and/or benefits.
- Funds are available for project expenses, technical assistance, patient expenses, research supplies and durable laboratory equipment (under $2000) used for the purposes of this project, analysis software, national registries, survey licenses, etc.
- Indirect costs (institutional overhead) will NOT be funded.
- The proposal must be typed in Cambria 12 pt. type with page margins no less than .5 inches and no more than 1 inch.
- Pagination should be included at the bottom of each page (excluding the Title page).
- The entire application must be submitted as ONE PDF FILE to firstname.lastname@example.org, by 4pm EST on March 31, 2022. SUBJECT LINE: RPLA APPLICATION SUBMISSION
- Regulatory Requirements
- Human and/or animal use must be approved by the Institutional Review Board or Institutional Animal Care and Use Committee, or their equivalent and documented before funds are released, but pre-approval is not required for application.
- It is required that any research involving human embryos will comply with applicable federal and state laws and will be in line with the ASRM’s guidance document on the ethics of human embryo research. No research will proceed without all relevant Institutional Board(s) and Committee(s) reviews and approval.
An ASRM Research Institute Grant Review Group (GRG) in collaboration with the RPLA appointed designees, will review the proposals and an awardee determined. To avoid a potential conflict of interest, members of the GRG will recuse themselves from review of any proposal that involves their institutions of employment.
Award notifications will be made in April 2022 and funding will be dispersed May 2022.
Project Partnership and Deliverables
The project will have the following objectives:
- Furtherance of ASRM’s mission to advance the science of reproductive medicine
- Furtherance of RPLA’s mission to understand the diagnosis, management, and pathogenesis of recurrent pregnancy loss
- Increase awareness of RPLA among ASRM members
- Enable award recipients initiate innovative research projects into unexplained early pregnancy loss
The project will have the following deliverables:
- Increased insights and contributions to the field of knowledge of recurrent pregnancy loss.
- Increased awareness and attention to recurrent pregnancy loss and early miscarriage.
- Presentation of grant recipients’ research findings at an ASRM Congress within two years of receiving the award.
- Acknowledgement of RPLA and ASRM support in any publications, abstracts, manuscripts and/or presentations at scientific conferences or meetings resulting from the funded research.
Research progress and financial reports must be submitted to ASRM and RPLA annually; this should include an activity summary and review of current findings/results. A final research report is due within 60 days of the end date of the project period. The reporting requirements for the final report are the following: Lay Summary, Activity Summary, Impact, Budget Summary, Publications, Presentations, Data Sharing Plan, and Other Study Generated Findings.
Publication, Publicity, and Co-Branding
Publications, abstracts, manuscripts and/or presentations at scientific conferences or meetings based on results from the funded project must acknowledge RPLA and ASRM using the following language: “Funded in part by a grant from the Recurrent Pregnancy Loss Association in partnership with the American Society for Reproductive Medicine.” Results and research findings must be presented at the ASRM Congress within two years of receiving the award and copy of any published works should be sent to the Board of Directors of RPLA and ASRM Research Institute.
The names of the Investigator and institution as well as the project title, a description of the project, and information regarding the award (written or digital) may be listed on the RPLA website (www.rplassociation.org), ASRM Research Institute website (www.asrmresearch.org), social media pages, or in print & digital written materials.